Expandable Prostheses in Pediatric Oncology

Expandable endoprostheses represent a critical advancement in pediatric musculoskeletal oncology, enabling limb salvage in skeletally immature patients while accommodating ongoing skeletal growth. Without expandable technology, children with significant remaining growth would face limb length discrepancy greater than 4cm following tumour resection that includes the growth plate.

Physeal Growth Contribution

Accurate prediction of limb length discrepancy is essential for surgical planning. Growth contribution varies by anatomical site:

Lower Limb:

Upper Limb:

The Multiplier Method

The Multiplier Method (Paley) provides the most accurate prediction of limb length discrepancy using skeletal age:

Calculation Steps:

1. Obtain bone age radiograph (left hand and wrist)
2. Determine multiplier value from published tables based on skeletal age and sex
3. Calculate expected remaining growth: Remaining growth = Current limb length x (Multiplier - 1)
4. Predicted LLD = Remaining growth of affected side (which will be zero if physis resected)

Example Calculation:

A 10-year-old boy (skeletal age 10) with osteosarcoma of the distal femur requiring physeal resection. Current femoral length is 35cm. The multiplier for a 10-year-old boy is 1.28.

• Expected remaining femoral growth = 35 x (1.28 - 1) = 9.8cm
• Distal femoral contribution = 70% x 9.8cm = 6.9cm predicted LLD

This patient requires an expandable prosthesis.

Timing of Expansion

The Registry section of this topic invokes the Henderson failure-mode classification to standardise reporting, but the classification itself deserves development because it gives you the shared vocabulary examiners expect when discussing endoprosthetic complications. Henderson and colleagues reviewed 2,174 tumour endoprostheses across five institutions (534 failures) and defined five primary modes of failure, each stratified by amputation risk and treatment urgency:

This topic twice flags that the optimal duration of antibiotic prophylaxis for these high-risk implants is unsettled and names the PARITY collaboration. PARITY (Prophylactic Antibiotic Regimens In Tumour surgery) is the single highest-level piece of evidence in this entire field and directly answers that question, so it warrants a definitive statement rather than a passing mention.

PARITY was a blinded, multicentre randomised superiority trial across 48 sites in 12 countries. It enrolled patients with a primary bone tumour, a sarcoma invading the femur or tibia, or oligometastatic femoral/tibial disease who required excision and endoprosthetic reconstruction - the exact population that includes paediatric and adolescent limb-salvage patients. Patients were randomised to a 1-day versus a 5-day postoperative regimen of intravenous cephalosporin (cefazolin or cefuroxime).

When a skeletally immature child needs a growing or growth-equivalent reconstruction, the expandable endoprosthesis is one of several alternatives. Examiners expect you to compare them and justify your choice.

Immediate Post-operative

Rehabilitation Protocol

Conversion to Adult Prosthesis

Oncological Outcomes

Prosthesis Survival

Functional Outcomes

Global Epidemiology

Primary bone sarcomas of childhood and adolescence are rare worldwide (approximately 8-9 per million children/adolescents annually). Osteosarcoma and Ewing sarcoma dominate, with peak incidence during the pubertal growth spurt. The proportion needing a growing reconstruction is driven by age at presentation and tumour site - distal femoral and proximal tibial lesions most often require growth-accommodating implants because they straddle the most active lower-limb physes.

Side-by-Side Guidance

Across all major bodies the principles converge: referral to a specialist sarcoma centre, MDT decision-making, R0 resection before reconstruction, and shared decision-making with family. Genuine differences are organisational (network structure) rather than oncological.

Registry and Outcome Notes

There is no dedicated international registry for paediatric expandable prostheses; evidence is dominated by single-centre and multi-institutional case series (Level IV). Adult tumour-endoprosthesis registries and the Henderson failure-mode classification (soft tissue, aseptic loosening, structural, infection, tumour progression) are widely applied to standardise reporting. Collaborative groups (e.g. PARITY trial network for infection prophylaxis) are improving the evidence base.

High- vs Limited-Resource Practice Variation

• Well-resourced centres: Non-invasive magnetic/electromagnetic systems (REPIPHYSIS, JTS, Stanmore non-invasive) with outpatient lengthening; 3D-printed custom implants; routine MDT and long-term surveillance.
• Limited-resource settings: Higher reliance on modular/minimally invasive expansion or non-expandable reconstruction; rotationplasty and amputation remain important, durable, cost-effective options where growing implants or repeated lengthening logistics are not feasible.
• Universal principle: Implant choice should match the local capacity for repeated follow-up, expansion, and revision - a sophisticated implant without reliable surveillance can underperform a simpler, durable reconstruction.

Unresolved questions for the literature:

• No randomised data compare expandable endoprosthesis with rotationplasty or biological reconstruction; all comparisons are Level IV.
• Patient-reported and long-term quality-of-life outcomes are inconsistently reported, limiting true device comparison.
• Optimal antibiotic prophylaxis duration for these high-risk implants is still being defined (informed by broader tumour-endoprosthesis infection trials).